Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies
Abstract
Background: Emerging evidence supports the use of Janus kinase inhibitors (JAKi) in acute severe ulcerative colitis (ASUC). However, risk factors associated with non-response and the need for short-term colectomy in ASUC patients treated with JAKi remain poorly understood.
Methods: We conducted a systematic review and individual-level data meta-analysis of real-world studies evaluating tofacitinib or upadacitinib for the treatment of ASUC. The primary and secondary outcomes were colectomy within 30 days and 12 weeks, respectively. Generalized linear mixed-effects models were used for univariable and multivariable analyses to estimate odds ratios (ORs). A stratified Cox proportional hazards model was used to assess colectomy-free survival.
Results: Twenty-three studies with 145 patients were included (69.0% treated with tofacitinib, 31.0% with upadacitinib). The overall colectomy rate was 13.1% within 30 days and 20.5% within 12 weeks. In univariable analyses, prior exposure to anti-tumor necrosis factor (TNF) therapy before ASUC hospitalization was statistically significantly associated with lower odds of colectomy within 30 days (OR 0.44, P = .006) and 12 weeks (OR 0.51, P = .008). Prior anti-TNF exposure remained significantly associated with lower odds of colectomy in multiple multivariable analyses. No other clinical or laboratory variables were significantly associated with primary/secondary outcomes.
Conclusions: Prior anti-TNF exposure before hospitalization is associated with lower short-term colectomy rates in ASUC patients treated with JAKi. Our findings highlight the need for future studies to optimize the position of JAKi in the ASUC management algorithm and to identify novel predictive biomarkers to advance precision medicine strategies.
Related
- Urgent Colectomy for Colonic Necrosis Following Shiga Toxin-Producing Escherichia coli O157 Infection in an Adult.
- SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes
- Continuous Infusion Versus Intermittent Bolus Proton Pump Inhibitor Therapy Following Endoscopic Hemostasis for Bleeding Peptic Ulcers: A Systematic Review and Meta-Analysis
- Reduced‐Port Versus Multi‐Port Laparoscopic Colectomy for Colorectal Cancer: A Systematic Review, Meta‐Analysis, and Meta‐Regression
- The Efficacy and Safety of Etrasimod for the Induction and Maintenance of Remission in Moderate to Severe Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis of Randomised Controlled Trials
BibTeX
@article{zou2026risk,
title = {{Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies}},
author = {Yuntao Zou and David I Fudman and Shrinivas Bishu and Jeffrey A Berinstein and Ezra Burstein and Moheb Boktor and Jianyi Yin},
journal = {Crohn's \& Colitis 360},
year = {2026},
month = oct,
doi = {10.1093/crocol/otag120},
url = {https://doi.org/10.1093/crocol/otag120},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Risk factors of short-term colectomy following Janus kinase inhibitor therapy in acute severe ulcerative colitis: a systematic review and meta-analysis of individual-level data from real-world studies
AU - Yuntao Zou
AU - David I Fudman
AU - Shrinivas Bishu
AU - Jeffrey A Berinstein
AU - Ezra Burstein
AU - Moheb Boktor
AU - Jianyi Yin
PY - 2026
DA - 2026/10/23
JO - Crohn's & Colitis 360
DO - 10.1093/crocol/otag120
UR - https://doi.org/10.1093/crocol/otag120
AB - Background: Emerging evidence supports the use of Janus kinase inhibitors (JAKi) in acute severe ulcerative colitis (ASUC). However, risk factors associated with non-response and the need for short-term colectomy in ASUC patients treated with JAKi remain poorly understood. Methods: We conducted a systematic review and individual-level data meta-analysis of real-world studies evaluating tofacitinib or upadacitinib for the treatment of ASUC. The primary and secondary outcomes were colectomy within 30 days and 12 weeks, respectively. Generalized linear mixed-effects models were used for univariable and multivariable analyses to estimate odds ratios (ORs). A stratified Cox proportional hazards model was used to assess colectomy-free survival. Results: Twenty-three studies with 145 patients were included (69.0% treated with tofacitinib, 31.0% with upadacitinib). The overall colectomy rate was 13.1% within 30 days and 20.5% within 12 weeks. In univariable analyses, prior exposure to anti-tumor necrosis factor (TNF) therapy before ASUC hospitalization was statistically significantly associated with lower odds of colectomy within 30 days (OR 0.44, P = .006) and 12 weeks (OR 0.51, P = .008). Prior anti-TNF exposure remained significantly associated with lower odds of colectomy in multiple multivariable analyses. No other clinical or laboratory variables were significantly associated with primary/secondary outcomes. Conclusions: Prior anti-TNF exposure before hospitalization is associated with lower short-term colectomy rates in ASUC patients treated with JAKi. Our findings highlight the need for future studies to optimize the position of JAKi in the ASUC management algorithm and to identify novel predictive biomarkers to advance precision medicine strategies.
SN - 2631-827X
ER -